VICORE PHARMA HOLDING AB chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/Akr (N/A)
Beta 0.82
Market capitalization 2.14B
Operating cash flow -276.57M
ESG Scores unknown

Company description

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 9.31M 3.32M 26.55M 27.41M
Total Cashflows From Investing Activities 15.03M -77.15M 4M -7M
Net Borrowings
Total Cash From Financing Activities 218.68M 127.04M 176.97M 318.18M
Change To Operating Activities
Issuance Of Stock 232.42M 134.83M 187.55M 336M
Net Income -21.68M -93.08M -146.86M -296.48M
Change In Cash 200.67M -37.1M 61.03M 45.58M
Effect Of Exchange Rate -431k -431k -431k -431k
Total Cash From Operating Activities -33.04M -87M -119.94M -265.17M
Depreciation 7k 1.34M 3.54M 3.6M
Change To Account Receivables -1.27M 234k -3.87M -340k
Other Cashflows From Financing Activities -13.74M -7.79M -10.58M -17.82M
Change To Netincome -19.4M 1.19M 709k 639k
Capital Expenditures -147k -147k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 26.86M 67.05M 142.02M 271.81M
Income Before Tax -21.68M -93.33M -147.31M -296.74M
Net Income -21.68M -93.08M -146.86M -296.48M
Selling General Administrative 14.84M 26.88M 24.99M 21.61M
Gross Profit 508k
Ebit -41.19M -93.92M -167.01M -293.42M
Operating Income -41.19M -93.92M -167.01M -293.42M
Interest Expense -352k -27k -6k -2.56M
Income Tax Expense -245k -453k -254k
Total Revenue 508k
Cost Of Revenue
Total Other Income ExpenseNet 19.51M 594k 19.69M -3.31M
Net Income From Continuing Ops -21.68M -93.08M -146.86M -296.48M
Net Income Applicable To Common Shares -21.68M -93.08M -146.86M -296.48M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 16.16M 19.51M 52M 67.85M
Total Stockholder Equity 285.44M 321.6M 354.51M 383.32M
Other Current Liabilities 730k 3.63M 7.48M 1.6M
Total Assets 301.6M 341.11M 406.51M 451.17M
Common Stock 16.48M 25.09M 30.21M 35.88M
Other Current Assets
Retained Earnings -137.8M -230.89M -377.75M -674.23M
Treasury Stock 4.41M
Cash 224.69M 187.59M 248.62M 294.2M
Total Current Liabilities 13.91M 16.95M 48.09M 65.72M
Other Stockholder Equity 4.41M
Property, Plant, and Equipment 21k 332k 252k 401k
Total Current Assets 226.82M 266.51M 327.85M 377.93M
Net Tangible Assets 216.24M 253.51M 283.76M 315.89M
Net Receivables 1.62M 1.43M 8.51M 1.42M
Accounts Payable 2.38M 5.3M 10.94M 23.98M


Insider Transactions

Here are the insider transactions of stock shares related to VICORE PHARMA HOLDING AB:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to VICORE PHARMA HOLDING AB. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on VICORE PHARMA HOLDING AB

Here is the result of two systematic investment strategies applied to VICORE PHARMA HOLDING AB. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on VICORE PHARMA HOLDING AB

The following chart shows the equity curve of the two systematic investment strategies applied to VICORE PHARMA HOLDING AB:

VICORE PHARMA HOLDING AB automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -20.72% on the backtest period.

Performance at glance

Performance

-20.72 %

Latent gain

-106.78 kr

Invested capital

515.26 kr

Annualized return

-26.56 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on VICORE PHARMA HOLDING AB

This is the result of two momentum investment strategies applied to VICORE PHARMA HOLDING AB. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on VICORE PHARMA HOLDING AB

The following chart shows all the entries opened by the momentum investment system on VICORE PHARMA HOLDING AB:

VICORE PHARMA HOLDING AB momentum entries
  • The first momentum investment strategy would give -20.25% of return on VICORE PHARMA HOLDING AB. That represents -246.36kr of latent gain with 1216.5kr of employed capital.
  • The second momentum investment strategy would give -16.98% of return on VICORE PHARMA HOLDING AB. That represents -41.76kr of latent gain with 246.0kr of employed capital.
Performance at glance (1Q Momentum)

Performance

-20.25 %

Latent gain

-246.36 kr

Invested capital

1216.5 kr

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

-16.98 %

Latent gain

-41.76 kr

Invested capital

246.0 kr

Annualized return

-56.6 %

Momentum equity curve on VICORE PHARMA HOLDING AB

The following chart shows the equity curve of the two momentum strategies applied to VICORE PHARMA HOLDING AB:

VICORE PHARMA HOLDING AB momentum equity

Note: the dividends potentially given by VICORE PHARMA HOLDING AB are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VICORE PHARMA HOLDING AB

The following chart shows the employed capital evolution of the two momentum strategies on VICORE PHARMA HOLDING AB since the beginning:

VICORE PHARMA HOLDING AB

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250kr, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000kr.


Buy the dip strategy result on VICORE PHARMA HOLDING AB

Buy the dip entry openings on VICORE PHARMA HOLDING AB

VICORE PHARMA HOLDING AB

The performance achieved by the robo-advisor on VICORE PHARMA HOLDING AB is 0%. That represents 0.0$ of latent gain with 0.0kr of employed capital. The following chart shows VICORE PHARMA HOLDING AB stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of VICORE PHARMA HOLDING AB, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 kr

Invested capital

0.0 kr

Annualized return

-0.0 %

Equity curve of the strategy applied to VICORE PHARMA HOLDING AB

The following chart shows the result of the investment strategy applied to VICORE PHARMA HOLDING AB:

VICORE PHARMA HOLDING AB

Note: the dividends potentially given by VICORE PHARMA HOLDING AB are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VICORE PHARMA HOLDING AB

The following chart shows the employed capital evolution since the beginning of the investment strategy on VICORE PHARMA HOLDING AB:

VICORE PHARMA HOLDING AB

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on VICORE PHARMA HOLDING AB

In this section, I will compare the three previous investment strategies applied to VICORE PHARMA HOLDING AB.

Equity curve comparison on VICORE PHARMA HOLDING AB

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

VICORE PHARMA HOLDING AB investment strategy comparison

Employed capital comparison on VICORE PHARMA HOLDING AB

VICORE PHARMA HOLDING AB investment comparison

Performance comparison on VICORE PHARMA HOLDING AB

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -20.72% -106.78kr 515.26kr -26.56%
Momentum 1 quarter -20.25% -246.36kr 1216.5kr -37.5%
Momentum 2 quarters -16.98% -41.76kr 246.0kr -56.6%
Non-directional 0% 0.0kr 0.0kr -0.0%
Annualized return comparison

Automatic investment

-26.56 %

Momentum 1Q

-56.6 %

Momentum 2Q

-56.6 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with VICORE PHARMA HOLDING AB:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between VICORE PHARMA HOLDING AB and the other stocks. There may be false positives or some missing correlated stocks. If the price of VICORE PHARMA HOLDING AB does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name VICORE PHARMA HOLDING AB
Country Sweden
City Gothenburg
Address Kronhusgatan 11
Phone 46 3 17 88 05 60
Website www.vicorepharma.com
FullTime employees 21
Industry Biotechnology
Sector Healthcare
Exchange XSTO
Ticker VICO.XSTO
Market www.nasdaqomxnordic.com

VICORE PHARMA HOLDING AB ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown